Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Melanoma 1Lung Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Healthy Volunteers 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Craniopharyngioma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

lutetium Lu 177 dotatate 4Temozolomide 4anlotinib 3Specimen Handling 3cabozantinib 2belzutifan 2Sunitinib 2Magnetic Resonance Spectroscopy 2Axitinib 23-Iodobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2talazoparib 1pembrolizumab 1pazopanib 1olaparib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1ONC206 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Paraganglioma × Contrast Media × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡